What does this research mean for the field?

The ArteraAI multimodal artificial intelligence (MMAI) model significantly improves the prediction of biochemical recurrence (BCR) and distant metastases (DM) in localized prostate cancer compared to standard prognostic criteria. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

This research aims to validate a previously-developed AI-derived biomarker using data from the CHHiP trial to improve prostate cancer treatment personalization.

March 4, 2026

External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived prognostic biomarker in the randomised phase III CHHiP trial.

Puntos clave

This research aims to validate a previously-developed AI-derived biomarker using data from the CHHiP trial to improve prostate cancer treatment personalization.
Central review of H&E slides by a uro-pathologist from CHHiP trial patients.
Gleason grade group reassigned in 52% of cases based on updated guidelines.
Evaluation of the ArteraAI prostate MMAI algorithm incorporating age, T-stage, and PSA with digital biopsy images.
Performed multivariable Cox regression analysis for biochemical recurrence and distant metastasis.
Assessed the added prognostic value of MMAI compared to established risk models using Concordance Index and Likelihood Ratio Test.
Among 1797 patients with sufficient data, high MMAI scores correlated with a significantly greater risk of biochemical recurrence and distant metastases.
MMAI High risk showed a hazard ratio of 5.07 for biochemical recurrence, while the MMAI Intermediate risk had a hazard ratio of 1.90.
Incorporating MMAI into existing risk models substantially improved prediction accuracy for both biochemical recurrence and distant metastases.

Resumen

308 Background: Risk stratification in localised prostate cancer (PCa) based on clinicopathological parameters is inadequate, leading to under- and over-treatment. We used CHHiP trial data to externally validate a previously-developed MMAI prognostic model with potential for cost-effective improved treatment personalisation. Methods: H trial primary endpoint) and development of distant metastases (DM) were performed with models including age and MMAI as continuous (per 0.1 increase) and categorical (ArteraAI pre-validated 3-tier risk groups) variables. The additional prognostic value of MMAI beyond UK-recommended Cambridge Prognostic Group (CPG) and NCCN risk group models was assessed by change in Concordance Index and Likelihood Ratio Test (LRT). Results: Of 1854 patients with centrally-reviewed pathology, 1797 (97%) had clinical data and H&E with sufficient tumour for MMAI analysis. Median follow up was 14.3 years. Patients were classified as MMAI High (129, 7.2%), Intermediate (885, 49.2%) or Low (783, 43.6%). In univariable analysis, high MMAI score was significantly associated with increased BCR risk, as both a categorical variable (MMAI High risk hazard ratio (HR) = 5.07, 95%CI = 3.77-6.81, p=<0.001, MMAI Intermediate-risk HR = 1.90, 1.52-2.36, p=<0.001), and continuous variable (MMAI raw score HR = 1.55, 1.44-1.67, p=<0.001). MMAI was also significantly associated with DM. Addition of MMAI to CPG and NCCN multivariable models significantly improves discrimination (C-index) and overall fit (change in LRT) for BCR and DM (Table 1). Conclusions: ArteraAI MMAI improves prediction of BCR and DM in CHHiP over standard criteria. This first large-scale external validation in a contemporary UK cohort of localised PCa with rigorously standardized care will inform future prospective trials of MMAI biomarker-guided PCa treatment selection. Endpoint Model C index (MMAI risk group) ΔLRT χ² (p) C index (MMAI raw score) ΔLRT χ² (p) BCR CPG + ageCPG + age + MMAI 0.620.65+0.03 p=<0.001 55.6 p=<0.001 0.620.67+0.05 p=<0.001 67.5 p=<0.001 BCR NCCN + ageNCCN + age + MMAI 0.590.64+0.05 p=<0.001 67.2 p=<0.001 0.590.66+0.07 p=<0.001 80.9 p=<0.001 DM CPG + ageCPG + age + MMAI 0.650.71+0.06 p=0.001 35.3 p=<0.001 0.650.73+0.08p=<0.001 47.0 p=<0.001 DM NCCN + ageNCCN + age + MMAI 0.610.70+0.09 p=<0.001 43.4 p=<0.001 0.610.72+0.11 p=<0.001 55.8 p=<0.001 Total, n=1794. Events BCR, n = 426 (23.7%), DM, n = 121 (6.7%).

Preguntar a la IA

Me gusta

Guardar